



Food and Drugs Authority Safety Monitoring Department/ National Pharmacovigilance Center

Adverse Reaction Reporting Scoreboard

Outlook of Regional Performance

Every two months, the Safety Monitoring Department/ National Pharmacovigilance Center of the FDA releases the Adverse Reaction Reporting Scoreboard, which provides quantitative data on training programs and individual case safety reports (ICSRs) from the sixteen regions. The goal of the scoreboard is to compare reporting trends of adverse reactions to drugs, immunizations, and other health-related issues at the regional levels in order to improve diagnosis, management and reporting of safety issues. This is expected to increase the number of adverse events that are recorded and to identify new safety signals for products including vaccines, marketed drugs and other healthcare products. This edition highlights PV activities between March and April 2024.

Pharmacovigilance Training Programs

The FDA had 37 pharmacovigilance (PV) training programs between March to April 2024 in the 16 regions with a total of 1,387 participants consisting of practicing and student healthcare professionals. Cumulatively, 157 training programs were carried out with Ashanti region recording the highest number of PV meetings followed by Greater Accra region. Figure 1 shows the performance of the regions in terms of the number of PV training programs.




Fig. 1: The number of PV training programs organized in the regions.

Figure 2 shows the percentage of the professional backgrounds of the participants trained during the PV training programs.




Fig. 2: Professional background of participants for the PV training programs in percentage.

Adverse Reactions Reported

Two hundred and twenty-nine (229) ICSRs were received for medicines, vaccines and other health products during the period under review. The Greater Accra region recorded the highest absolute number of reports (Figure 3). In terms of reporting rate, Greater Accra, Ahafo and Bono East regions had ICSR reporting rate of 4 reports per 100,000 population (Figure 4) based on the 2021 population and housing census.




Fig. 3. Number of adverse reaction reports received in the region.




Fig. 4: Regional reporting rate per 100,000 population (2021 Population and Housing Census)

Get in touch with us on the underlisted contacts for any information on the safety of your medicines, vaccines, and other health products:

Telephone : 024 4310 297

Email : drug.safety@fda.gov.gh